Immune checkpoint inhibitors improved survival of melanoma patients and severalstrategies have been developed towards the improvement of their efficacy and activity.If the combination of anti-PD-1 and anti CTLA-4 is a new efficient immunotherapyregimen, promising results derive from the associations of immunocheckpoint inhibitorsand the different systemic agents. Here, CTLA4 is linked to melanoma.